Barclays Notes the Payoffs From The Aetna & Coventry Deal

Barclays’ research review of the recent acquisition of Coventry Health Care, Inc. (NYSE:CVH) by Aetna Inc. (NYSE:AET) is highly appreciative of the merger.

Though the stock rating for Aetna Inc. (NYSE:AET) is maintained unchanged at Overweight, and so is the Price Target at $55, it would be useful to look at the many factors that are highlighted in the report, and which are expected to work in favor of the acquisition.

1. On an overall basis,...

   Membership Required

   You must be a member to access this content.

   Already a member? Log in here